Abstract

Multiple human diseases including cancer have been associated with a dysregulation in RNA splicing patterns. In the current study, modifications to the global RNA splicing landscape of cellular genes were investigated in the context of Epstein-Barr virus-associated gastric cancer. Global alterations to the RNA splicing landscape of cellular genes was examined in a large-scale screen from 295 primary gastric adenocarcinomas using high-throughput RNA sequencing data. RT-PCR analysis, mass spectrometry, and co-immunoprecipitation studies were also used to experimentally validate and investigate the differential alternative splicing (AS) events that were observed through RNA-seq studies. Our study identifies alterations in the AS patterns of approximately 900 genes such as tumor suppressor genes, transcription factors, splicing factors, and kinases. These findings allowed the identification of unique gene signatures for which AS is misregulated in both Epstein-Barr virus-associated gastric cancer and EBV-negative gastric cancer. Moreover, we show that the expression of Epstein–Barr nuclear antigen 1 (EBNA1) leads to modifications in the AS profile of cellular genes and that the EBNA1 protein interacts with cellular splicing factors. These findings provide insights into the molecular differences between various types of gastric cancer and suggest a role for the EBNA1 protein in the dysregulation of cellular AS.

Highlights

  • Gastric carcinoma (GC) is the second leading cause of cancer-related deaths worldwide [1]

  • We initially focused our study on EBV-associated gastric carcinomas (EBVaGC) (EBVaGC, that are altered in EBVaGC (TEBV), Tumors with Epstein-Barr virus (EBV)), and we compared the splicing patterns with normal tissues (NNoV, Normal tissues, no virus)

  • To identify the cellular alternative splicing (AS) patterns that are modified in EBVaGC, we evaluated the modifications in the relative splice abundances by quantifying all the primary RNA transcripts that produce two or more isoforms

Read more

Summary

Introduction

Gastric carcinoma (GC) is the second leading cause of cancer-related deaths worldwide [1]. The clinical outcome for patients with GC remains poor, with a 5-year survival rate of only about 20% [2]. Most patients with GC are diagnosed with advanced stage disease, resulting in a dismal prognosis and highlighting the importance of the identification of diagnostic and prognostic markers [3]. Epstein-Barr virus (EBV) infection is associated with 10% of all GC cases reported worldwide [4].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call